ETF Holdings Breakdown of AMRX

Stock NameAmneal Pharmaceuticals, Inc. Class A Common Stock
TickerAMRX(USD) NYSE
TYPECommon Stock
CountryUSA
ISINUS03168L1052
LEI549300VV176ZO5WQHZ61

News associated with AMRX

Voya Investment Management LLC Has $384,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Voya Investment Management LLC cut its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 6.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 48,488 shares of the company’s stock after selling 3,442 shares during the period. Voya […] - 2025-05-11 09:06:55
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Upgraded by StockNews.com
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “buy” rating to a “strong-buy” rating in a report released on Monday. A number of other equities analysts have also recently weighed in on the stock. Barclays upped their price target on shares of Amneal Pharmaceuticals from $10.00 […] - 2025-05-07 06:06:47
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 5.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,991,702 shares of the company’s stock after acquiring an additional 278,653 shares during the quarter. […] - 2025-05-05 08:18:54
Raymond James Financial Inc. Invests $2.95 Million in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Raymond James Financial Inc. bought a new stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 371,996 shares of the company’s stock, valued at approximately $2,946,000. Several other institutional investors also recently added to or reduced […] - 2025-04-29 08:05:11
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.80 Consensus PT from Analysts
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has earned a consensus recommendation of “Buy” from the five analysts that are presently covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy rating. The average 1-year target price among analysts that have updated their coverage on the stock in the last […] - 2025-04-22 05:20:56
Wellington Management Group LLP Sells 8,577 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Wellington Management Group LLP trimmed its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 10.4% in the fourth quarter, HoldingsChannel reports. The firm owned 74,019 shares of the company’s stock after selling 8,577 shares during the quarter. Wellington Management Group LLP’s holdings in Amneal Pharmaceuticals were worth $586,000 as of its […] - 2025-04-15 08:32:51
Federated Hermes Inc. Purchases 5,849 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Federated Hermes Inc. lifted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 2.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 271,834 shares of the company’s stock after buying an additional 5,849 shares during the period. […] - 2025-04-14 08:15:03
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Arrowstreet Capital Limited Partnership
Arrowstreet Capital Limited Partnership reduced its position in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 25.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,541,058 shares of the company’s stock after selling 527,921 shares during the […] - 2025-04-06 08:27:00
Swiss National Bank Acquires 31,900 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Swiss National Bank lifted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 274,000 shares of the company’s stock after purchasing an additional 31,900 shares during the quarter. Swiss National Bank’s […] - 2025-03-28 07:54:50
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Bought by Principal Financial Group Inc.
Principal Financial Group Inc. grew its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 9.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 96,835 shares of the company’s stock after purchasing an additional 8,213 shares during the quarter. Principal Financial Group Inc.’s holdings in Amneal Pharmaceuticals were worth $767,000 as […] - 2025-03-07 08:21:06
Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Target Price at $10.60
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Buy” by the five research firms that are currently covering the stock, Marketbeat Ratings reports. Five research analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the […] - 2025-03-05 06:55:12
Rhumbline Advisers Acquires 7,875 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Rhumbline Advisers boosted its position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 3.5% in the fourth quarter, HoldingsChannel.com reports. The firm owned 232,264 shares of the company’s stock after acquiring an additional 7,875 shares during the period. Rhumbline Advisers’ holdings in Amneal Pharmaceuticals were worth $1,840,000 as of its most recent SEC filing. […] - 2025-03-04 08:12:48
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Y Intercept Hong Kong Ltd
Y Intercept Hong Kong Ltd lifted its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 55.3% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 58,111 shares of the company’s stock after purchasing an additional 20,686 shares during the period. Y Intercept Hong Kong Ltd’s […] - 2025-03-03 08:28:58
Amneal Pharmaceuticals (NASDAQ:AMRX) Rating Increased to Overweight at JPMorgan Chase & Co.
Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) was upgraded by analysts at JPMorgan Chase & Co. from a “neutral” rating to an “overweight” rating in a note issued to investors on Monday, Marketbeat Ratings reports. The firm presently has a $12.00 price objective on the stock, up from their previous price objective of $9.00. JPMorgan […] - 2025-02-26 07:01:03
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Short Interest Down 18.0% in January
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) saw a significant decline in short interest in January. As of January 31st, there was short interest totalling 2,420,000 shares, a decline of 18.0% from the January 15th total of 2,950,000 shares. Currently, 1.9% of the shares of the company are sold short. Based on an average […] - 2025-02-17 08:44:56
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $10.00 Average PT from Brokerages
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the five brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target […] - 2025-02-06 06:06:55
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Acquires 5,523 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)
Empirical Financial Services LLC d.b.a. Empirical Wealth Management increased its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Free Report) by 13.6% in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 46,240 shares of the company’s stock after purchasing an additional 5,523 shares […] - 2025-01-30 08:57:13

AMRX institutional holdings

The following institutional investment holdings of AMRX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 77,223USD 576,084 3.2%
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 13,062USD 97,443 3.2%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 147,886USD 1,103,230 3.2%
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 147,886USD 1,103,230 3.2%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 519USD 3,872 3.2%
Total =386,576 USD 2,883,859
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.